Eli Lilly pays $55m to gain rights to diabetes treatments

Eli Lilly has entered into a collaboration agreement with KeyBioscience, a subsidiary of Nordic Bioscience, to commercialise dual amylin calcitonin receptor agonists (DACRAs).

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Court narrows Mylan’s Copaxone suit but key claims survive

14 April 2026 A US district court has allowed key elements of the generic drugmaker’s case against a rival to move forward, while drawing clear limits on how far the complaint can reach.

Americas

LSPN Awards USA: Meet the judges

10 April 2026 The 2026 panel has been chosen. With judges from Amgen, Pfizer, Eli Lilly, Takeda, Regeneron and law firms such as White & Case and Arnold & Porter, here’s who will be deciding this year’s winners.

Americas

Bausch reaches deal with competitor over IBS drug generic

7 April 2026 According to the settlement, MSN can maintain its challenge to several Bausch patents, while the details around potential product launch timings are unknown.

More features

Court narrows Mylan’s Copaxone suit but key claims survive

IP finance gap risks startup exodus, EUIPO warns

Oracle retaliates with lawsuit to laid-off staff member’s ‘demands’

LSPN Awards USA: Meet the judges

UK patent office adopts EPO standards for AI inventions

Faegre Drinker boosts FDA regulatory practice with two senior hires

Gilead to pay up to $5bn for antibody-drug conjugates push

Closing the women's health gap offers ‘benefits for all’

Eli Lilly pays $55m to gain rights to diabetes treatments

More on this story

Editor's picks

Editor's picks

More features